| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1470-2045(18)30442-X |
| P698 | PubMed publication ID | 30115595 |
| P2093 | author name string | James O Armitage | |
| Avyakta Kallam | |||
| P2860 | cites work | Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study | Q33432228 |
| Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | Q33438494 | ||
| Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia | Q35958056 | ||
| Venetoclax and obinutuzumab in chronic lymphocytic leukemia | Q42348732 | ||
| Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. | Q52644817 | ||
| Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial | Q90986748 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 1143-1144 | |
| P577 | publication date | 2018-08-13 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Venetoclax in chronic lymphocytic leukaemia: a possible cure? | |
| P478 | volume | 19 |
Search more.